For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 20,532,670 | |||
| Acquisition-related costs (note 5) | 3,679,618 | |||
| General and administrative expenses | 7,583,651 | |||
| Operating loss | 31,795,939 | |||
| Employee retention tax credit | 113,574 | |||
| Grant income | 713,508 | |||
| Interest expense | 625,283 | |||
| Interest income | 136,233 | |||
| Change in fair value of kineta merger holdback shares | 1,590,949 | |||
| Loss on kineta employee separation payments assumed from merger | 185,019 | |||
| Total other income (expense) | 1,743,962 | |||
| Net loss | -30,051,977 | |||
| Series a preferred cash dividend | 8,356 | |||
| Deemed dividend on warrant modifications | 0 | |||
| Net loss attributable to common stockholders | -30,060,333 | |||
| Basic EPS | -0.63 | |||
| Diluted EPS | -0.63 | |||
| Basic Average Shares | 47,927,196 | |||
| Diluted Average Shares | 47,927,196 | |||
TuHURA Biosciences, Inc. NV (HURA)
TuHURA Biosciences, Inc. NV (HURA)